Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
3 Gene Editing Stocks With Unprecedented Surge Potential
06:05am, Tuesday, 13'th Feb 2024
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
01:15pm, Thursday, 08'th Feb 2024
With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:50am, Wednesday, 07'th Feb 2024
Cathie Wood purchased shares of Palantir, Tesla, and Intellia Therapeutics yesterday. She tends to buy some of her favorite stocks when they take a hit, but Palantir soared 31% on Tuesday after a well
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
12:28pm, Wednesday, 31'st Jan 2024
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
05:10am, Tuesday, 30'th Jan 2024
The S&P 500 has increased about 35% in this new bull market -- but if history is a guide, gains have just gotten started. Past bull markets have lasted much longer than bear markets.
Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround
10:36am, Monday, 29'th Jan 2024
Intellia Therapeutics, Inc. (NTLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street an
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
01:25pm, Saturday, 27'th Jan 2024
The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more
Is It Too Late to Buy Intellia Therapeutics Stock?
08:55am, Saturday, 27'th Jan 2024
Intellia Therapeutics has a promising candidate about to enter late-stage testing. The company has a couple of exciting earlier-stage programs, too.
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
05:41pm, Monday, 22'nd Jan 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with substantial catalysts and make a fortune.
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
08:00am, Sunday, 21'st Jan 2024
Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.
Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?
09:47am, Friday, 12'th Jan 2024
Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
07:45am, Monday, 08'th Jan 2024
Intellia Therapeutics and Editas Medicine are pre-revenue biotechs. Editas is a long way from commercializing its first medicine.
Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts
10:04am, Friday, 05'th Jan 2024
Intellia Therapeutics (NASDAQ: NTLA ) layoffs are a hot topic on Friday as the company prepares to cut jobs following an internal strategic review. According to a press release from Intellia Therapeut
2 gene-editing stocks reshaping hereditary disease treatments
07:16am, Tuesday, 02'nd Jan 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle
3 Biotechs With Promising Gene Therapies in the Spotlight
09:47am, Wednesday, 13'th Dec 2023
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.
